VIGOR

(redirected from Vioxx Gastrointestinal Outcomes Research)
AcronymDefinition
VIGORVioxx Gastrointestinal Outcomes Research
VIGORVegetarian Information Group of Rochester (Rochester, MN)
VIGORVolunteers in Government of Responsibility (New Orleans, LA)
References in periodicals archive ?
Trial names used in this review ADAPT: Alzheimer's Disease Anti-inflammatory Prevention Trial APC: Adenoma Prevention with Celecoxib APPROVe: Adenomatous Polyp Prevention on Vioxx CLASS: Celecoxib Long-term Arthritis Safety Study MEDAL programme: Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme PreSAP: Prevention of colorectal Spontaneous Adenomatous Polyps TARGET: Therapeutic Arthritis Research and Gastrointestinal Event Trial VIGOR: Vioxx Gastrointestinal Outcomes Research Table II.
In the Vioxx Gastrointestinal Outcomes Research (VIGOR) trial, 8,076 rheumatoid arthritis patients were randomized to rofecoxib 50 mg/day or naproxen 1,000 mg/day.
s Vioxx (rofecoxib) to include results from the landmark 8,000-patient Vioxx Gastrointestinal Outcomes Research (VIGOR) study.